Anti-CD100 antibodies and methods of using the same

Patent metadata

Field	Value
Publication number	US-9605055-B2
Application number	US-201313797048-A
Country	US
Kind code	B2
Filing date	Mar 12, 2013
Priority date	May 8, 2009
Publication date	Mar 28, 2017
Grant date	Mar 28, 2017

Abstract

Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.

First claim

What is claimed is:

1. A method for treating a cancer in an animal in need of treatment, comprising administering to said animal a composition comprising: an isolated antibody or antigen-binding fragment thereof that specifically binds to CD100, wherein the antibody or fragment thereof comprises a VH polypeptide comprising VH-CDR1, VH-CDR2, and VH-CDR3 amino acid sequences comprising SEQ ID NOs: 6, 7, and 8, respectively, and a VL polypeptide comprising VL-CDR1, VL-CDR2, and VL-CDR3 amino acid sequences comprising SEQ ID NOs: 14, 15, and 16, respectively; and a pharmaceutically acceptable carrier.

2. The method of claim 1 wherein said antibody or fragment thereof inhibits CD100 binding to a CD100 receptor.

3. The method of claim 2 , wherein said CD100 receptor is Plexin-B1.

4. The method of claim 1 , wherein said animal is a mammal.

5. The method of claim 4 , wherein said mammal is a human.

6. The method of claim 1 , wherein the VH of said antibody or antigen-binding fragment thereof comprises the amino acid sequence SEQ ID NO: 9 or SEQ ID NO: 10.

7. The method of claim 1 , wherein the VL of said antibody or antigen-binding fragment thereof comprises the amino acid sequence SEQ ID NO: 17 or SEQ ID NO: 18.

8. The method of claim 1 , wherein the VH and VL of said antibody or antigen-binding fragment thereof comprise the amino acid sequences SEQ ID NO: 9 and SEQ ID NO: 17, respectively, or SEQ ID NO: 10 and SEQ ID NO: 18, respectively.

9. The method of claim 1 , wherein CD100 is expressed by the cancer cells, by inflammatory cells present in a tumor microenvironment, or both.

10. The method of claim 1 , wherein the cancer is head and neck cancer, prostate cancer, colon cancer, breast cancer, lung cancer, or any combination or metastases thereof.

11. The method of claim 1 , wherein antibody or antigen-binding fragment thereof is administered in combination with another cancer therapy, wherein the other cancer therapy is chemotherapy, radiation therapy, anti-cancer antibody therapy, small molecule-based cancer therapy, or vaccine/immunotherapy-based cancer therapy.

Assignees

• Vaccinex Inc

Inventors

• Smith Ernest S
• Fisher Terrence Lee

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/02

  Immunomodulators · CPC title